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Towards more accurate solubility measurements
with real time monitoring: a carvedilol case study†
Dóra Csicsák,a Enik +o Borbás, *b Szabina Kádár,b Petra T +ozsér,b Péter Bagi, b
Hajnalka Pataki,b Bálint Sinkó,c Krisztina Takács-Nováka and Gergely Völgyi a
The aim of this study was to draw attention to the challenges of solubility measurement and to present
new techniques and detection methods that provide more accurate results. We investigated the effect
of crystal structure, pH and buffer composition on thermodynamic equilibrium solubility using two
polymorphs of carvedilol (Form I and Form II) as model compounds. Measuring the solubility of
carvedilol is challenging, as the literature data show extremely high standard deviation. Therefore
standardized measurements were performed in the pH range 3–10, in two solutions at 25 1C: Britton–
Robinson (BR) and BR with added KCl. Solid phase analysis was performed by X-ray powder diffraction
and Raman spectroscopy. The measured SpH data were compared to the theoretical Henderson–Hassel-
balch (HH) curve and a perfect fit was found in the pH range 7–10. The salt formation could be
observed in the acidic pH range. The counter-ion and solubility of the salt were found to be different in
various buffer solutions. In situ fiber optic UV probes were used to monitor the dissolution of carvedilol
polymorphs in real-time. The results showed significantly different dissolution kinetics for the
polymorphs depending on the pH and the buffer solution. From the dissolution profile, the time
required to reach the equilibrium was determined. In most cases, it was more than 24 hours, therefore
using the standard protocol (6 hours agitation, 18 hours sedimentation) would have caused significant
inaccuracy in results. In extreme cases the measured concentration after 24 hours was found to be 5 or
6 times higher than the real equilibrium solubility.
1. Introduction
Solubility is one of the most important physicochemical
properties of a drug for the pharmaceutical industry. It can
highly influence the absorption of a compound and
consequently affect bioavailability. It is also a key parameter
in the Biopharmaceutics Classification System (BCS).1
Solubility is influenced by the lattice structure of a compound.
Because of the different lattice energies, the dissolution
requires more or less solvation energy.2 Polymorphism is the
ability of the compounds to exist in two or more crystalline
structures, consequently it can affect their solubility or
dissolution.3 As a rule of thumb, the polymorph having the
lower lattice-free energy is the more stable form and it has
lower solubility while the one with higher energy is less stable
but tends to dissolve faster and has higher solubility.4
Polymorphism can be observed at least for one-third of the
active pharmaceutical ingredients. The topic received increasing
attention in the past decades, as more and more cases with
unexplored polymorphism caused serious safety problems.5
Cases with the highest publicity (chloramphenicol palmitate,
oxytetracycline, enalapril, ritonavir) are discussed in detail in the
literature.6–9 As the result, the discovery and investigation of
possible polymorphs (i.e. polymorph screening) is now an
inevitable requirement in drug development. Solubility difference
of polymorphs will affect the bioavailability/bioequivalence of a
drug product if the solubility is the rate-limiting factor upon
absorption (for BCS II and IV drugs).
Equilibrium (or thermodynamic) solubility is the concen-
tration of the compound in a saturated solution when the solid
and solution phases are at equilibrium. This parameter can be
measured by several methods, however, the ‘‘gold standard’’ is
still the saturation shake-flask (SSF) technique.10 The kinetic
solubility (not a thermodynamic constant) is the concentration
when precipitation first appears in the (saturated or super-
saturated) solution. It can be registered with an in situ device,
such as fiber optic UV probes. The kinetic solubility is generally
higher than the measured equilibrium solubility.11 In the case
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of ionisable molecules, solubility depends on the pH of the
medium: acidic molecules have poorer solubility at acidic pH;
basic molecules at alkaline pH. For amphoteric molecules, the
lowest solubility can be observed at their isoelectric point.12–14
The solubility of the unionized form of the compound can be
described by the intrinsic solubility value (So).
Solubility measurement of polymorphs is often challenging
since in the presence of solvent changes in the crystalline
structure of the compound can be observed: the less stable
form can be converted to the more stable form; depending on
the solvent, a hydrate or solvate may be formed. Because of
these phenomena, the solubility measurements of polymorphs
must always be complemented by solid-phase analysis to
identify the form present in the equilibrium.15
In this work, carvedilol was used as a model compound to
study the possible behaviour of polymorphs in solubility
experiments. Carvedilol (CAS No. 72956-09-3) is a non-selective
beta-adrenergic receptor blocker and an alpha-adrenergic
receptor blocker, that acts on the beta-1 receptors of the heart
to produce negative inotropic and chronotropic effects.
Therefore it is primarily used to treat hypertension. However,
due to its non-selective nature, it can cause bronchoconstriction
on the beta-2 receptors in the lungs, which limits its
applicability.16 Carvedilol is known to have many polymorphic
forms, in this study Form I and II were used.17–19 Several studies
published solubility data of carvedilol, but the intrinsic solubility
values show poor reproducibility. The average value is log So [M]:
5.35  0.47 (in-ADME Research).20 In the literature different
methods (CheqSol, SSF method), buffers (NaOH/HCl solution,
phosphate, acetate buffers, FaSSIF/FeSSIF media) and phase
separation techniques (centrifugation, sedimentation, filtration)
were described.21–25 These circumstances can greatly influence
the measured equilibrium solubility, so this work tried to avoid
as many potential errors as possible.26 Therefore real-time
monitoring was used via immersed UV probes, because it
needed no phase-separation and the sensitivity of UV detection
is appropriate to measure the concentration of carvedilol
solutions.
This study aimed to follow the dissolution of the two
polymorphs of the model compound in different buffer solutions
using real-time monitoring, to determine the equilibrium solubility
over a wide pH range and to obtain detailed information about
supersaturation and the time needed to reach the equilibrium.
Furthermore, the reason for the poor reproducibility of the intrinsic
solubility data found in the literature was also investigated.
2. Experimental section
2.1 Materials
The structure of the model compound is presented in Fig. 1.
Carvedilol was purchased from Merck KGaA. (Darmstadt,
Germany). From the commercially available Form II, the other
polymorphic form (Form I) was prepared in-house based on
patents and literature data17–19 and was verified by X-Ray
powder diffraction (XRPD) and differential scanning calorimetry
(DSC) measurements. Distilled water of Ph. Eur. grade was used.
All other reagents were of analytical grade.
As solvent, two different buffer solutions were used: Britton–
Robinson (BR) buffer stock solution (a mixture of acetic acid,
phosphoric acid, and boric acid, each at 0.04 M) and modified
BR buffer, where 0.15 M KCl was added to the solution (BR + KCl).
The required amount of 0.2 M NaOH or 1 M NaOH was added to
obtain the pH specified for the solubility experiments in the pH
range 3–10.
2.2 Solubility measurements
2.2.1 In situ monitoring of the dissolution profile. The
drug solution concentration versus time was investigated with
the mDISS ProfilerTM. The operation of this device is based on
UV spectrophotometry using fiber optic UV probes for in situ
concentration measurements.27–29 The instrument measures
the real-time concentration with fiber optic UV dip probe
inserted in 6 temperature-controlled 20 mL vessels, stirred with
a magnetic stirrer. Using the appropriate tips (2–5–10–20 mm
pathlength) adjusted to the UV probe, the UV spectra were
registered in the following timing protocol: 1 spectrum per 30 s
in 0–1 h, 1 spectrum per 1 min in 1–6 h and per 2 min in 6–24 h
periods. In some cases, the UV spectra were further registered
at two points in a 24–66 h period. The stirrer was turned off 6
hours before the end of the measurements. For the evaluation
of the concentration, previously determined calibration data
and second derivative spectra were used. The calibration was
performed using a DMSO stock solution for each UV dip probe
separately. Equivalently small amount of this solution was
added to all vessels, and after each step, the UV spectrum
was registered. From the known concentration values and UV
data, the calibration curve was determined with linear regression
(R2 Z 0.9990 in each case). To get accurate concentration data
the calibration was performed at each pH and buffers. The
equilibrium solubility was also determined from the dissolution
curve in some cases.
2.2.2 Equilibrium solubility. The equilibrium solubility of
the samples in the examined pH region was determined by the
SSF method. The sample was added in excess to the aqueous
buffer solutions to produce a suspension. The amount of solid
was accurately weighed: 10–16 mg/20 mL. At a controlled
temperature of 25.0  0.1 1C, the solution containing solid
excess of the sample was vigorously stirred generally for
60 hours (agitation time) followed by a sedimentation period
of 6 hours before the end of the measurements. In special
cases, where reaching the equilibrium lasted longer than
60 hours, longer measurement time was used. mDISS ProfilerTM
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(Pion Inc. Billerica MA, US) was applied as the UV fiber optic
instrumentation. The equilibrium concentration was concomi-
tantly determined in situ in the equilibrated solubility system
(without dilution) by immersing the appropriate UV dip probe.
Calibration was performed with the same (2–5–10–20 mm) tip
adjusted to the fiber optic UV dip probe which was used in the
given solubility experiment. The concentration was determined
by the AU Pro software (Pion Inc. Billerica MA, US) using the
second derivative method in the range 278–289 nm.
2.3 Solid-phase analysis
2.3.1 Raman spectroscopy. At the end of the solubility
measurement, a small amount of the solid phase was isolated
and dried on a glass plate. Raman spectra were collected using
a Horiba Jobin-Yvon LabRAM system coupled with an Olympus
97 BX-40 optical microscope (Olympus Corporation, Tokyo,
Japan). The sample was illuminated by a 785 nm diode laser
(TEC 510 type, Sacher Lasertechnik, Marburg, Germany) and an
objective of 10 (laser spot size, approximately 4 mm) was used
for optical imaging and spectrum acquisition. The laser beam
was focused through the objective, and the backscattered
radiation was collected with the same objective, a common
configuration found in most confocal spectroscopic systems.
The collected radiation was directed through an edge filter that
removed the Rayleigh photons and then through a confocal
hole (500 mm) and the entrance slit (100 mm). Finally, a
950 groove per mm grating monochromator dispersed the
Raman photons before reaching the CCD detector. Each
spectrum of the image was collected in the spectral range of
300 to 1600 cm1.
2.3.2 XRPD. X-Ray powder diffraction patterns were used to
verify the results of the Raman measurements in the questionable
cases and to collect more detailed information if needed. The
same samples were used as in the case of Raman spectroscopy.
The measurement was carried out by a PANalytical (Amelo, The
Netherlands) X’pert ProMDP X-ray diffractometer using Cu-Ka
radiation (1.524 Å) and a Ni filter. The applied voltage was 40 kV,
while the current was 30 mA. The samples were analyzed between
41 and 421 2Y.
2.4 Statistical analyses
Concentrations were expressed as means  SD, and were
compared using the ‘‘two-sample’’ Student’s t-test. Differences
were considered statistically significant when p o 0.05.
3. Results and discussion
Carvedilol is a non-selective b-receptor blocker drug used
mainly as an antihypertensive agent in immediate-release (IR)
tablets as a racemate of the free base form and in retard tablets
as that of its phosphate salt, respectively. The compound
belongs to the BCS II group having low solubility and high
permeability.30 Carvedilol is known to have many polymorphic
forms, in this study Form I and II (nomenclature according to
Pataki et al.17,18) were used. In recent literature, Form I is
referred as Form III.31 Although Form I is more stable (melting
point: 123–126 1C), in marketed formulations Form II (melting
point: 114–115 1C) is used. Form I and Form II are monotropic
forms.18 Carvedilol is a monoprotic base, (pKa: 8.06), its
solubility is pH-dependent in the biorelevant pH range.
3.1 Real-time dissolution monitoring by lDISS Profiler
The dissolution profile of the examined carvedilol polymorphs
was followed in real-time via UV fiber-optic probes in BR or BR
+ KCl buffers. The dissolution kinetics was found highly
different depending on the pH and the buffer solution.
In Fig. 2 the dissolution kinetics of the two polymorphs in BR
and BR + KCl buffer solutions can be seen at pH 4, which is
representative of the acidic pH region. In the BR buffer,
practically no difference could be observed, within 3 hours
both forms reached the equilibrium solubility of the phosphate
salt, which formed in the acidic range (pH 3–5). No change was
observed until the end of the measurements (Fig. 2, A panel).
On the other hand in the BR + KCl buffer solution, Form II
reached a higher supersaturation at 310 mg mL1 and held it a
bit longer before reaching the equilibrium solubility of the
hydrochloride salt (Fig. 2, B/2 panel). From the dissolution
profile, the time required to reach the equilibrium can be
determined. It was less than 24 hours in the acidic pH region,
so in this case, the use of the standard protocol (18 hours
agitation time, 6 hours sedimentation) was found to be
appropriate.10,12
At pH 8 (which represents the basic pH region), both Form I
and Form II exhibit immediate dissolution with no or minimal
supersaturation. Equilibrium solubility concentrations can be
seen on the first panel of Fig. 3. The second panel shows the
deviation between the dissolution of the two polymorphs in the
first 15 hours. Not only lower equilibrium solubility, but also
slower dissolution can be observed in the case of Form I. Both
Fig. 2 Concentration–time profile of carvedilol polymorphs at pH 4 in BR
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Form I and II needed more than one day to reach equilibrium
solubility, therefore measuring the concentration after 24 hours
can lead to false solubility data. After one day, the concentration
of the solution of Form I was 2.96  0.03 mg mL1, which is 14%
higher than the measured concentration at the real equilibrium.
In contrast, Form II slowly reached the equilibrium state without
supersaturation, and the concentration obtained after 24 hours
was 30% lower than the equilibrium solubility. In this basic
region (pH 7–10) no salt formation could be observed.
The greatest difference between the behavior of the two
polymorphs can be observed at pH 6. Fig. 4 shows that Form
II exhibits immediate dissolution and reaches supersaturation
with 135 mg mL1, at ca. 40 min. Form I dissolves much slower,
producing a lower supersaturation at ca. 400 min (Fig. 4, A/2
panel). The total solubility-time profile (Fig. 4, A/1 panel)
indicates that it precipitates quickly from the saturated
solution but the system reaches the real solubility equilibrium
state of the phosphate salt very slowly, during ca. 3 days.
Reaching the equilibrium state is even slower in the presence
of KCl, where hydrochloric salt is forming at the end of the
measurement. However, the kinetics in the first few hours is
very similar to the dissolution profile in BR buffer solution
(Fig. 4, B/2 panel). Form I reached the equilibrium in BR + KCl
at ca. 5 days, in contrast, Form II needed even more time,
approx. 9 days (Fig. 4, B/1 panel). This slow equilibrium can
cause inaccuracy if the standard 24 hours protocol is applied.
In the BR buffer solution, the concentration of Form I after
24 hours is 85.95  3.74 mg mL1, which is 20.9% higher
than the real equilibrium concentration. This distortion is
only 7.6% in the case of Form II. In BR + KCl, this deviation
is significantly higher: the concentration of Form I after
24 hours is 112.01  5.81 mg mL1 and the concentration of
Form II is 91.56  0.71 mg mL1. It causes a more than
600% increase compared to the actual equilibrium solubility
in the case of Form I and more than 500% in the case of
Form II.
3.2 Solubility-pH profile of carvedilol polymorphs
The pH-dependent equilibrium solubility of carvedilol Form I
and Form II was studied at 25 1C, in the pH 3–10 range, in
BR buffer solutions (chloride ion free, I = 0.089 M) and also in
pH 3–6.5 domain in BR buffer solutions using external
salt (KCl) to adjust the ionic strength to 0.15 M. The average
values of the solubility results in mg mL1 unit are collected in
Table 1.
The standard deviation was found to be in the range of
1–35%, the average was 8%. A significant difference in
equilibrium solubility of the two polymorphs was found in
the pH range 7–10, Form II reached twice as high equilibrium
concentration as Form I. This solubility ratio of polymorphs is
in agreement with the general behavior of polymorphs reported
in the literature.32 The experimental data showed a perfect fit to
the theoretical HH curve (log S [M] vs. pH, Fig. 5) between pH
7–10. At about pH 6.5, the measured solubility starts to deviate
from the HH curve; in the presence of KCl, a constant
Fig. 4 Concentration–time profile of carvedilol polymorphs at pH 6 in BR
and BR + KCl buffers.
Table 1 Equilibrium solubility of carvedilol polymorphs in BR and BR + KCl buffers measured by mDISS device
Sample pH SpH  SD (mg mL1) BR pH SpH  SD (mg mL1) BR + KCl Sample pH SpH  SD (mg mL1) BR pH SpH  SD (mg mL1) BR + KCl
Form I 3.38 437.84  32.64 3.08 13.54  0.45 Form II 3.30 491.42  18.79 3.12 13.01  1.10
4.16 342.37  2.68 4.09 14.54  1.22 4.17 334.77  6.96 4.10 14.09  0.71
5.08 165.49  8.54 5.05 12.76  1.34 5.12 158.22  7.34 5.08 15.19  1.96
6.05 71.06  2.45 6.06 18.05  1.84 6.12 68.19  2.50 6.06 18.01  1.82
6.57 35.63  1.84 6.62 46.91  0.68
6.99 11.75  0.20 6.99 22.04  0.21
8.02 2.59  0.19 8.06 4.61  0.55
8.95 1.23  0.15 8.96 2.38  0.85
9.98 1.21  0.06 9.84 2.23  0.38
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salt solubility can be observed at pH 3–6. This is a typical
phenomenon when a salt starts to precipitate from the
solution. In contrast, the equilibrium concentrations measured
in the pure BR buffer at pH 3–6 show a continually increasing
tendency and reach no constant value. Solid-phase analysis
methods helped to identify which salt is formed in the different
buffer media.
3.3 Characterization of the undissolved solid phase isolated
from solubility measurements
In the pH range 7–10, the Raman spectra of the solid phase
isolated from the solubility suspension after equilibration
showed consentaneous characteristic peaks with the starting
materials (Fig. 6). This supports that during the solubility
Fig. 5 Solubility-pH profile of carvedilol Form I and Form II in BR and BR + KCl buffers (solid line represents the theoretical HH curve, points represent
the experimental data).
Fig. 6 Raman spectra of original Form I, Form II and the solid phase
of carvedilol polymorphs isolated from solubility suspensions from the
measurements at pH 7 and 10.
Fig. 7 Raman spectra of carvedilol hydrochloride and the solid phase
of carvedilol polymorphs isolated from solubility suspensions from the

































































































This journal is © The Royal Society of Chemistry and the Centre National de la Recherche Scientifique 2021 New J. Chem., 2021, 45, 11618–11625 |  11623
experiments, the transition did not happen and the measured
solubility belongs to the specified polymorph.
In the pH range 3–5, salt formation can be observed regardless
of the starting polymorph, but in a different way in the two buffers
used. Hydrochloride salt (Fig. 7) was identified from the BR + KCl
buffer, while a phosphate salt from pure BR buffer, which was
identified as carvedilol dihydrogen phosphate anhydrate
(later referred as phosphate salt) based on information found in
international patents.33,34
Since XRPD and Raman spectroscopy verified the identical
composition of the precipitate from pH 3–5 BR solutions
(Fig. 8), the increasing solubility with decreasing pH in this
region (see Table 1 and Fig. 5) can be explained by the
formation of solute aggregates or complexes with a buffer
component.
At pH 6.5, the two polymorphs showed different behavior at
the end of the solubility measurements in the BR buffer
solution. Form II formed a phosphate salt. It can be observed
that the Raman spectra and the XRPD diffractogram differ from
that of the original Form II and show characteristic peaks with
the phosphate salt. In contrast, Raman spectra and XRPD
diffractogram of the sample from the end of the solubility
measurements of Form I shows a good agreement with the
original form, except one peak, which can be observed between
700 and 750 cm1 at the Raman spectra and between 17 and 19
2Y at the XRPD diffractogram (Fig. 9), and is characteristic to
the phosphate salt.
In conclusion it can be stated, based on solubility and
solid-phase measurements, that the solubility of Form I and
carvedilol dihydrogen phosphate anhydrate is so similar, that
Fig. 8 Raman spectra (left) and XRPD diffractogram (right) of carvedilol dihydrogen phosphate anhydrate and the solid phase of carvedilol polymorphs
isolated from solubility suspensions from the measurements at pH 3 and 5 in BR.
Fig. 9 Raman spectra (left) and XRPD diffractogram (right) of carvedilol dihydrogen phosphate anhydrate, Form I, Form II and the solid phase of
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the original compound cannot be completely transformed into
the salt at pH 6.5. It also means that the pHmax is slightly
different in the case of the two polymorphs. The pHmax refers to
the pH where both the phosphate salt and the carvedilol free
base have equal solubilities. This phenomenon can be observed
only in the BR buffer solution because in BR + KCl the solubility
of the hydrochloride salt is much lower at this pH.
4. Conclusion
In this study, we have demonstrated that the poorly water-
soluble carvedilol provides a good example that BCS II classi-
fied drugs may need more than 24 hours to reach their
equilibrium solubility. Factors like the type of polymorph,
pH, and even the buffer composition can greatly influence
the equilibration time. This can explain the different equili-
brium solubility values of carvedilol published in the literature.
In the case of carvedilol, real-time monitoring of the dissolu-
tion was found to be essential in order to measure the solubility
at the true equilibrium.
The use of in situ UV probes enabled the measurement of
concentration in real-time without sampling and sample pre-
paration and provided a more in-depth knowledge of how the
equilibrium is reached in case of different polymorphic forms.
In most cases, Form II showed a faster dissolution and reached
a higher extent of supersaturation. The faster dissolution of
Form II at biorelevant pHs explains the application of the less
stable polymorph in solid formulations.
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Excellence Program of the Ministry for Innovation and Tech-
nology from the source of the National Research, Development,
and Innovation Fund.
Notes and references
1 G. L. Amidon, H. Lennernäs, V. P. Shah and J. R. Crison,
Pharm. Res., 1995, 12, 413–420.
2 A. Avdeef, Absorption and Drug Development: Solubility, Per-
meability, and Charge State, 2012.
3 T. L. Threlfall, Analyst, 1995, 120, 2435–2460.
4 H. G. Brittain, Polymorphism in Pharmaceutical Solids, 2nd
edn, 2016.
5 P. A. Pangarkar, A. M. Tayade, S. G. Uttarwar and
R. S. Wanare, Int. J. Pharm. Technol., 2013, 5, 2374–2402.
6 R. Eyjolfsson, Pharmazie, 2002, 57, 347–348.
7 D. Tempfli, E. Borbás, H. Pataki, D. Csicsák, G. Völgyi,
B. Sinkó and K. Takács-Novák, Eur. J. Pharm. Sci., 2020,
149, 105328.
8 J. Bauer, S. Spanton, R. Henry, J. Quick, W. Dziki, W. Porter
and J. Morris, Pharm. Res., 2001, 18, 859–866.
9 A. J. Aguiar, J. Krc, A. W. Kinkel and J. C. Samyn, J. Pharm.
Sci., 1967, 56, 847–853.
10 E. Baka, J. E. A. Comer and K. Takács-Novák, J. Pharm.
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Novák, G. Völgyi, B. Sinkó and Z. K. Nagy, Mol. Pharmaceu-
tics, 2018, 15, 3308–3317.
31 L. D. Prado, H. V. A. Rocha, J. A. L. C. Resende, G. B. Ferreira
and A. M. R. De Figuereido Teixeira, CrystEngComm, 2014,
16, 3168–3179.
32 M. Pudipeddi and A. T. M. Serajuddin, J. Pharm. Sci., 2005,
94, 929–939.
33 R. K. Thaper, M. D. Prabhvat, A. V. Mouneshwarachar, Y. D. Pawar,
P. P. Daramwar and P. R. Upadhyay, WO2008093350A1, 2007.
34 J. Hildesheim, S. Finogueev, J. Aronhime, B.-Z. Dolitzky,
S. Ben-Valid and I. Kor, US Pat., US7056942B2, 2000.
Paper NJC
O
pe
n 
A
cc
es
s 
A
rt
ic
le
. P
ub
lis
he
d 
on
 1
0 
Ju
ne
 2
02
1.
 D
ow
nl
oa
de
d 
on
 9
/2
1/
20
21
 1
2:
33
:3
8 
PM
. 
 T
hi
s 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
C
om
m
on
s 
A
ttr
ib
ut
io
n-
N
on
C
om
m
er
ci
al
 3
.0
 U
np
or
te
d 
L
ic
en
ce
.
View Article Online
